carbamates has been researched along with Hypoglycemia in 43 studies
Hypoglycemia: A syndrome of abnormally low BLOOD GLUCOSE level. Clinical hypoglycemia has diverse etiologies. Severe hypoglycemia eventually lead to glucose deprivation of the CENTRAL NERVOUS SYSTEM resulting in HUNGER; SWEATING; PARESTHESIA; impaired mental function; SEIZURES; COMA; and even DEATH.
| Excerpt | Relevance | Reference |
|---|---|---|
| " However, its blood concentration has been reported to increase in combination with clopidogrel, an antiplatelet drug, and in patients with severe renal insufficiency." | 8.02 | Hypoglycemia during the Concomitant Use of Repaglinide and Clopidogrel in an Elderly Patient with Type 2 Diabetes and Severe Renal Insufficiency. ( Fujii, K; Hazama, Y; Kosugi, M; Miyoshi, Y; Nagata, S; Obata, Y; Takayama, K; Uehara, Y; Yamaguchi, H; Yasuda, T, 2021) |
| "This case illustrates that in the context of overdose, repaglinide can lead to prolonged hypoglycemia." | 7.83 | Prolonged hypoglycemia after a suicidal ingestion of repaglinide with unexpected slow plasma elimination. ( Auwaerter, V; Elling, R; Hermanns-Clausen, M; Spehl, MS; Wohlfarth, A, 2016) |
| "To report a case of clinically significant hypoglycemia attributed to the concomitant use of trimethoprim/sulfamethoxazole (TMP/SMX) and repaglinide by a diabetic patient." | 7.76 | Symptomatic hypoglycemia associated with trimethoprim/sulfamethoxazole and repaglinide in a diabetic patient. ( Blondel, E; Fonrose, X; Mallaret, MP; Roustit, M; Villier, C, 2010) |
| "Many drugs have been reported to interact with repaglinide in patients with type 2 diabetes mellitus, resulting in hypoglycemia." | 7.74 | Severe hypoglycemia from clarithromycin-repaglinide drug interaction. ( Khamaisi, M; Leitersdorf, E, 2008) |
| "We report the first case of repaglinide-induced factitious hypoglycemia in a young male." | 7.71 | Repaglinide-induced factitious hypoglycemia. ( Brennan, R; Csako, G; Gorden, P; Hirshberg, B; Pucino, F; Skarulis, MC, 2001) |
| "Insulin and glucose levels in response to premeal insulin lispro or repaglinide were evaluated in adult patients with cystic fibrosis-related diabetes (CFRD) without fasting hyperglycemia." | 7.71 | Insulin and glucose excursion following premeal insulin lispro or repaglinide in cystic fibrosis-related diabetes. ( Milla, C; Moran, A; Phillips, J, 2001) |
| "Repaglinide is an insulin secretion enhancer with a different mechanism of action to the sulphonylureas, which means it does not continuously stimulate insulin secretion." | 6.41 | [Repaglinide, potentially a therapeutic improvement for diabetes mellitus type 2]. ( Rutten, GE, 2001) |
| "This double-blind randomized placebo-controlled parallel group study assessed the efficacy and safety (with particular regard to body weight and hypoglycemia) of repaglinide when used in a flexible mealtime dosing regimen in a situation close to everyday clinical practice." | 5.09 | Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes. ( Dedov, I; Frandsen, KB; Gomis, R; Moses, RG; Schlienger, JL, 2001) |
| " The sulfonyluereas, repaglinide, metformin, acarbose and the thiazolidinediones are effective in decreasing fasting plasma glucose levels, but their limitations may include adverse effects, such as weight gain and hypoglycemia, and an inability to modify some of the important comorbidities of diabetes." | 4.80 | Advances in oral therapy for type 2 diabetes. ( Davis, SN, 2000) |
| " However, its blood concentration has been reported to increase in combination with clopidogrel, an antiplatelet drug, and in patients with severe renal insufficiency." | 4.02 | Hypoglycemia during the Concomitant Use of Repaglinide and Clopidogrel in an Elderly Patient with Type 2 Diabetes and Severe Renal Insufficiency. ( Fujii, K; Hazama, Y; Kosugi, M; Miyoshi, Y; Nagata, S; Obata, Y; Takayama, K; Uehara, Y; Yamaguchi, H; Yasuda, T, 2021) |
| "This case illustrates that in the context of overdose, repaglinide can lead to prolonged hypoglycemia." | 3.83 | Prolonged hypoglycemia after a suicidal ingestion of repaglinide with unexpected slow plasma elimination. ( Auwaerter, V; Elling, R; Hermanns-Clausen, M; Spehl, MS; Wohlfarth, A, 2016) |
| "To report a case of clinically significant hypoglycemia attributed to the concomitant use of trimethoprim/sulfamethoxazole (TMP/SMX) and repaglinide by a diabetic patient." | 3.76 | Symptomatic hypoglycemia associated with trimethoprim/sulfamethoxazole and repaglinide in a diabetic patient. ( Blondel, E; Fonrose, X; Mallaret, MP; Roustit, M; Villier, C, 2010) |
| "Many drugs have been reported to interact with repaglinide in patients with type 2 diabetes mellitus, resulting in hypoglycemia." | 3.74 | Severe hypoglycemia from clarithromycin-repaglinide drug interaction. ( Khamaisi, M; Leitersdorf, E, 2008) |
| "We report the first case of repaglinide-induced factitious hypoglycemia in a young male." | 3.71 | Repaglinide-induced factitious hypoglycemia. ( Brennan, R; Csako, G; Gorden, P; Hirshberg, B; Pucino, F; Skarulis, MC, 2001) |
| "Insulin and glucose levels in response to premeal insulin lispro or repaglinide were evaluated in adult patients with cystic fibrosis-related diabetes (CFRD) without fasting hyperglycemia." | 3.71 | Insulin and glucose excursion following premeal insulin lispro or repaglinide in cystic fibrosis-related diabetes. ( Milla, C; Moran, A; Phillips, J, 2001) |
| "More weight gain was detected in group 1, compared to the baseline." | 2.74 | The investigation of the efficacy of insulin glargine on glycemic control when combined with either repaglinide or acarbose in obese Type 2 diabetic patients. ( Duran, C; Ercan, I; Ersoy, C; Erturk, E; Guclu, M; Imamoglu, S; Kiyici, S; Selimoglu, H; Tuncel, E, 2009) |
| "The efficacy of twice-daily dosing of a repaglinide/metformin FDC tablet was non-inferior to that of three-times-daily dosing." | 2.74 | Twice-daily and three-times-daily dosing of a repaglinide/metformin fixed-dose combination tablet provide similar glycaemic control. ( Lewin, A; Lyness, W; Raskin, P; Reinhardt, R, 2009) |
| "In non-obese patients with type 2 diabetes and poor glycaemic regulation on oral hypoglycaemic agents, overall glycaemic regulation with insulin in combination with metformin was equivalent to that with insulin plus repaglinide." | 2.74 | Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial. ( Frandsen, M; Hansen, BV; Lund, SS; Nielsen, BB; Parving, HH; Pedersen, O; Tarnow, L; Vaag, AA, 2009) |
| "Pioglitazone dosage was fixed at 30 mg per day." | 2.71 | Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone. ( Gooch, B; Greco, S; Hale, PM; Hassman, DR; Jain, R; Jovanovic, L; Khutoryansky, N, 2004) |
| " After Ramadan, patients resumed their regular meal pattern and treatment dosage for 4 weeks." | 2.70 | Repaglinide versus glibenclamide treatment of Type 2 diabetes during Ramadan fasting. ( Mafauzy, M, 2002) |
| "Type 2 diabetes mellitus is characterised by abnormal beta-cell function (present at the time of diagnosis) that is often associated with insulin resistance." | 2.41 | Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes? ( Lauritzen, T; Nattrass, M, 2000) |
| "Repaglinide is an insulin secretion enhancer with a different mechanism of action to the sulphonylureas, which means it does not continuously stimulate insulin secretion." | 2.41 | [Repaglinide, potentially a therapeutic improvement for diabetes mellitus type 2]. ( Rutten, GE, 2001) |
| " The most common adverse event in the phase II studies was hypoglycaemia." | 2.40 | Preclinical and clinical studies on safety and tolerability of repaglinide. ( Schatz, H, 1999) |
| "Repaglinide is a new oral blood glucose lowering agent, a member of the carbamoylmethyl benzoic acid (CMBA) family." | 2.40 | Repaglinide--a new compound for the treatment of patients with type 2 diabetes. ( Wolffenbuttel, BH, 1999) |
| "Serious hypoglycemia is a major adverse event associated with insulin secretagogues." | 1.72 | Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia. ( Bilker, WB; Brensinger, CM; Flory, JH; Hee Nam, Y; Hennessy, S; Leonard, CE, 2022) |
| "8% of patients treated with a combination of a sulfonylurea and insulin knew this side effect of the OAD." | 1.48 | Hypoglycemic side effects of sulfonylureas and repaglinide in ageing patients - knowledge and self-management. ( Harsch, IA; Kaestner, RH; Konturek, PC, 2018) |
| "The self-controlled case series design has the potential to be widely applicable to screening for drug-drug interactions that lead to adverse outcomes identifiable in healthcare databases." | 1.46 | Biomedical Informatics Approaches to Identifying Drug-Drug Interactions: Application to Insulin Secretagogues. ( Bilker, WB; Brensinger, CM; Chiang, C; Han, X; Hennessy, S; Leonard, CE; Li, L, 2017) |
| "The treatment of newly diagnosed type 2 diabetes mellitus is diverse, with no clear consensus regarding the initial drug regimen or dosing to achieve optimal glycemic control." | 1.42 | Getting to goal in newly diagnosed type 2 diabetes using combination drug "subtraction therapy". ( George, TM; Jennings, AS; Jennings, JS; Lovett, AJ, 2015) |
| " plus single-dose insulin glargine regimen was safe for low-risk type 2 diabetic patients who insisted on fasting during Ramadan." | 1.35 | Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan. ( Bakiner, O; Bozkirli, E; Demirag, NG; Ertorer, ME; Tutuncu, NB, 2009) |
| "Treatment with nateglinide or repaglinide was characterized by a higher incidence of hypoglycaemia at the beginning of treatment." | 1.35 | Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide. ( Cornelius, V; Kasliwal, R; Shakir, SA; Vlckova, V; Wilton, L, 2009) |
| "Repaglinide is a novel oral antidiabetic agent, marking the development of a new class of drugs for type 2 diabetes." | 1.31 | Repaglinide: a novel oral antidiabetic agent. ( Nattrass, M, 2000) |
| "Nateglinide (A-4166) is an amino acid derivative with insulinotrophic action in clinical development for treatment of type 2 diabetes." | 1.31 | Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide. ( Bell, PA; Boettcher, BR; Dunning, BE; Fanelli, B; Geisse, S; Hu, S; Schmitz, R; Wang, S, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.65) | 18.7374 |
| 1990's | 4 (9.30) | 18.2507 |
| 2000's | 26 (60.47) | 29.6817 |
| 2010's | 9 (20.93) | 24.3611 |
| 2020's | 2 (4.65) | 2.80 |
| Authors | Studies |
|---|---|
| Takayama, K | 1 |
| Fujii, K | 1 |
| Yamaguchi, H | 1 |
| Miyoshi, Y | 1 |
| Uehara, Y | 1 |
| Nagata, S | 1 |
| Obata, Y | 1 |
| Kosugi, M | 1 |
| Hazama, Y | 1 |
| Yasuda, T | 1 |
| Hee Nam, Y | 1 |
| Brensinger, CM | 2 |
| Bilker, WB | 2 |
| Flory, JH | 1 |
| Leonard, CE | 2 |
| Hennessy, S | 2 |
| Omori, K | 1 |
| Nomoto, H | 1 |
| Nakamura, A | 1 |
| Takase, T | 1 |
| Cho, KY | 1 |
| Ono, K | 1 |
| Manda, N | 1 |
| Kurihara, Y | 1 |
| Aoki, S | 1 |
| Atsumi, T | 1 |
| Miyoshi, H | 1 |
| Harsch, IA | 1 |
| Kaestner, RH | 1 |
| Konturek, PC | 1 |
| Wei, Y | 1 |
| Lin, FJ | 1 |
| Lin, SY | 2 |
| Wang, CC | 1 |
| Mennecart, M | 1 |
| Mondon, K | 1 |
| Malherbe, C | 1 |
| Constans, T | 1 |
| Jennings, AS | 1 |
| Lovett, AJ | 1 |
| George, TM | 1 |
| Jennings, JS | 1 |
| Elling, R | 1 |
| Spehl, MS | 1 |
| Wohlfarth, A | 1 |
| Auwaerter, V | 1 |
| Hermanns-Clausen, M | 1 |
| Han, X | 1 |
| Chiang, C | 1 |
| Li, L | 1 |
| Bakiner, O | 1 |
| Ertorer, ME | 1 |
| Bozkirli, E | 1 |
| Tutuncu, NB | 1 |
| Demirag, NG | 1 |
| Duran, C | 1 |
| Tuncel, E | 1 |
| Ersoy, C | 1 |
| Ercan, I | 1 |
| Selimoglu, H | 1 |
| Kiyici, S | 1 |
| Guclu, M | 1 |
| Erturk, E | 1 |
| Imamoglu, S | 1 |
| Vlckova, V | 1 |
| Cornelius, V | 1 |
| Kasliwal, R | 1 |
| Wilton, L | 1 |
| Shakir, SA | 1 |
| Raskin, P | 2 |
| Lewin, A | 1 |
| Reinhardt, R | 1 |
| Lyness, W | 1 |
| Davis, SN | 1 |
| Fasano, CJ | 1 |
| Rowden, AK | 1 |
| Lund, SS | 1 |
| Tarnow, L | 1 |
| Frandsen, M | 1 |
| Nielsen, BB | 1 |
| Hansen, BV | 1 |
| Pedersen, O | 1 |
| Parving, HH | 1 |
| Vaag, AA | 1 |
| Roustit, M | 1 |
| Blondel, E | 1 |
| Villier, C | 1 |
| Fonrose, X | 1 |
| Mallaret, MP | 1 |
| Khamaisi, M | 2 |
| Mafauzy, M | 1 |
| Tankova, T | 1 |
| Koev, D | 1 |
| Dakovska, L | 1 |
| Kirilov, G | 1 |
| Lee, IT | 1 |
| Sheu, WH | 1 |
| Jovanovic, L | 1 |
| Hassman, DR | 1 |
| Gooch, B | 1 |
| Jain, R | 1 |
| Greco, S | 1 |
| Khutoryansky, N | 2 |
| Hale, PM | 2 |
| Kellerer, M | 1 |
| Jakob, S | 1 |
| Linn, T | 1 |
| Haslbeck, M | 1 |
| McGill, J | 1 |
| Saad, MF | 1 |
| Cappleman, JM | 1 |
| Kaye, W | 1 |
| Aldhahi, W | 1 |
| Armstrong, J | 1 |
| Bouche, C | 1 |
| Carr, RD | 1 |
| Moses, A | 1 |
| Goldfine, AB | 1 |
| Davies, MJ | 1 |
| Thaware, PK | 1 |
| Tringham, JR | 1 |
| Howe, J | 1 |
| Jarvis, J | 1 |
| Johnston, V | 1 |
| Kitchener, DL | 1 |
| Skinner, TC | 1 |
| McNally, PG | 1 |
| Lawrence, IG | 1 |
| Leitersdorf, E | 1 |
| Lilley, LL | 1 |
| Guanci, R | 1 |
| Moses, R | 1 |
| Schatz, H | 1 |
| Wolffenbuttel, BH | 1 |
| Nattrass, M | 2 |
| Hu, S | 1 |
| Wang, S | 1 |
| Fanelli, B | 1 |
| Bell, PA | 1 |
| Dunning, BE | 1 |
| Geisse, S | 1 |
| Schmitz, R | 1 |
| Boettcher, BR | 1 |
| Lauritzen, T | 1 |
| Hirshberg, B | 1 |
| Skarulis, MC | 1 |
| Pucino, F | 1 |
| Csako, G | 1 |
| Brennan, R | 1 |
| Gorden, P | 1 |
| Moses, RG | 1 |
| Gomis, R | 1 |
| Frandsen, KB | 1 |
| Schlienger, JL | 1 |
| Dedov, I | 1 |
| Owens, D | 1 |
| Rutten, GE | 1 |
| Moran, A | 1 |
| Phillips, J | 1 |
| Milla, C | 1 |
| Piroska, E | 1 |
| Kollin, E | 1 |
| Blickens, DA | 1 |
| Riggi, SJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Repaglinide and Metformin Combination Tablet (NN4440) in a TID Regimen Compared to a BID Regimen and BID Avandamet in Subjects With Type 2 Diabetes: A Twenty-Six Week, Open-Label, Multicenter, Randomized, Parallel Group Trial to Investigate Efficacy and S[NCT00399711] | Phase 3 | 560 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| Effect of Repaglinide Versus Metformin Treatment in Combination With Insulin Biasp30 (Novologmix 70/30) Predinner on Glycemic and Non-Glycemic Cardiovascular Risk-Factors in Non-Obese Patients With Type-2-Diabetes With Unsatisfactory Glycaemic Control Wit[NCT00118963] | Phase 4 | 102 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for carbamates and Hypoglycemia
| Article | Year |
|---|---|
Advances in oral therapy for type 2 diabetes.
Topics: Acarbose; Administration, Oral; Blood Glucose; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; | 2000 |
Severe hypoglycaemia from repaglinide-brotizolam drug interaction: a case report and literature review.
Topics: Aged; Azepines; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hyp | 2012 |
[Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy].
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Blood Glucose; Carbamates; Contraindications; Cyclohexanes; Diab | 2003 |
Preclinical and clinical studies on safety and tolerability of repaglinide.
Topics: Aged; Animals; Carbamates; Diabetes Mellitus, Type 2; Humans; Hypoglycemia; Hypoglycemic Agents; Pip | 1999 |
Repaglinide--a new compound for the treatment of patients with type 2 diabetes.
Topics: Administration, Oral; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Feeding Behavior; Humans | 1999 |
Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes?
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Eating; Humans; Hyp | 2000 |
The role of prandial glucose regulation with repaglinide in addressing the problem of hypoglycemia in the treatment of type 2 diabetes.
Topics: Carbamates; Diabetes Mellitus, Type 2; Humans; Hypoglycemia; Hypoglycemic Agents; Patient Compliance | 2001 |
[Repaglinide, potentially a therapeutic improvement for diabetes mellitus type 2].
Topics: Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glyburide; Humans; Hypoglycemia; H | 2001 |
12 trials available for carbamates and Hypoglycemia
| Article | Year |
|---|---|
Reduction in glucose fluctuations in elderly patients with type 2 diabetes using repaglinide: A randomized controlled trial of repaglinide vs sulfonylurea.
Topics: Aged; Aged, 80 and over; Biomarkers; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Female; F | 2019 |
The investigation of the efficacy of insulin glargine on glycemic control when combined with either repaglinide or acarbose in obese Type 2 diabetic patients.
Topics: Acarbose; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; G | 2009 |
Twice-daily and three-times-daily dosing of a repaglinide/metformin fixed-dose combination tablet provide similar glycaemic control.
Topics: Adult; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Ther | 2009 |
Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial.
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination | 2009 |
Repaglinide versus glibenclamide treatment of Type 2 diabetes during Ramadan fasting.
Topics: Biomarkers; Carbamates; Diabetes Mellitus, Type 2; Fasting; Feeding Behavior; Female; Fructosamine; | 2002 |
The effect of repaglinide on insulin secretion and oxidative stress in type 2 diabetic patients.
Topics: Carbamates; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Glycated Hemoglobin; Humans; | 2003 |
Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, | 2004 |
Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone.
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated He | 2004 |
Beta-cell insulin secretory response to oral hypoglycemic agents is blunted in humans in vivo during moderate hypoglycemia.
Topics: Administration, Oral; Adult; Carbamates; Cross-Over Studies; Double-Blind Method; Female; Glipizide; | 2004 |
A randomized controlled trial examining combinations of repaglinide, metformin and NPH insulin.
Topics: Adult; Aged; Aged, 80 and over; Carbamates; Diabetes Mellitus, Type 2; Drug Administration Schedule; | 2007 |
Repaglinide in combination therapy with metformin in Type 2 diabetes.
Topics: Australia; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemogl | 1999 |
Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes.
Topics: Aged; Blood Glucose; Body Weight; Carbamates; Diabetes Mellitus, Type 2; Diet; Double-Blind Method; | 2001 |
23 other studies available for carbamates and Hypoglycemia
| Article | Year |
|---|---|
Hypoglycemia during the Concomitant Use of Repaglinide and Clopidogrel in an Elderly Patient with Type 2 Diabetes and Severe Renal Insufficiency.
Topics: Aged; Blood Glucose; Carbamates; Clopidogrel; Diabetes Mellitus, Type 2; Humans; Hypoglycemia; Hypog | 2021 |
Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia.
Topics: Administrative Claims, Healthcare; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors | 2022 |
Hypoglycemic side effects of sulfonylureas and repaglinide in ageing patients - knowledge and self-management.
Topics: Aged; Aged, 80 and over; Aging; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fe | 2018 |
Risk of Hypoglycemia and Concomitant Use of Repaglinide and Clopidogrel: A Population-Based Nested Case-Control Study.
Topics: Aged; Aspirin; Carbamates; Case-Control Studies; Clopidogrel; Drug Interactions; Female; Humans; Hyp | 2019 |
Delayed hypoglycemia induced by repaglinide in a frail elderly adult with diabetes mellitus.
Topics: Aged, 80 and over; Carbamates; Diabetes Mellitus, Type 2; Frail Elderly; Humans; Hypoglycemia; Hypog | 2014 |
Getting to goal in newly diagnosed type 2 diabetes using combination drug "subtraction therapy".
Topics: Adult; Aged; Aged, 80 and over; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fe | 2015 |
Prolonged hypoglycemia after a suicidal ingestion of repaglinide with unexpected slow plasma elimination.
Topics: Adolescent; Blood Glucose; Carbamates; Chromatography, Liquid; Drug Overdose; Female; Half-Life; Hum | 2016 |
Biomedical Informatics Approaches to Identifying Drug-Drug Interactions: Application to Insulin Secretagogues.
Topics: Area Under Curve; Carbamates; Cyclohexanes; Databases, Factual; Diabetes Mellitus, Type 2; Drug Inte | 2017 |
Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan.
Topics: Adult; Aged; Blood Glucose; Blood Glucose Self-Monitoring; Blood Pressure; Carbamates; Diabetes Mell | 2009 |
Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide.
Topics: Administration, Oral; Adult; Adverse Drug Reaction Reporting Systems; Carbamates; Cohort Studies; Cy | 2009 |
Drug-induced hypoglycaemia.
Topics: Anti-Bacterial Agents; Blood Glucose; Carbamates; Dextropropoxyphene; Diabetes Mellitus; Disopyramid | 2009 |
Successful treatment of repaglinide-induced hypoglycemia with octreotide.
Topics: Aged, 80 and over; Carbamates; Gastrointestinal Agents; Humans; Hypoglycemia; Hypoglycemic Agents; M | 2009 |
Symptomatic hypoglycemia associated with trimethoprim/sulfamethoxazole and repaglinide in a diabetic patient.
Topics: Aged; Anti-Infective Agents, Urinary; Blood Glucose; Carbamates; Diabetes Complications; Diabetes Me | 2010 |
Hypoglycemia probably due to accidental intake of repaglinide.
Topics: Adolescent; Carbamates; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Medication Errors; Piperi | 2002 |
Severe hypoglycemia from clarithromycin-repaglinide drug interaction.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Blood Glucose; Carbamates; Clarithromycin; Diabetes Mellit | 2008 |
Drug knowledge is critical.
Topics: Aged; Carbamates; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemia; Hypoglycemic A | 1998 |
Repaglinide: a novel oral antidiabetic agent.
Topics: Administration, Oral; Blood Glucose; Body Weight; Carbamates; Diabetes Mellitus, Type 2; Humans; Hyp | 2000 |
Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide.
Topics: Animals; ATP-Binding Cassette Transporters; Binding, Competitive; Carbamates; Cell Membrane; Cell Se | 2000 |
Repaglinide-induced factitious hypoglycemia.
Topics: Adolescent; Blood Glucose; Carbamates; Diagnosis, Differential; Fasting; Humans; Hypoglycemia; Hypog | 2001 |
Repaglinide and diabetes: new preparation. No better than glucose-lowering sulphonamides.
Topics: Anti-Infective Agents; Carbamates; Diabetes Mellitus, Type 2; Humans; Hypoglycemia; Hypoglycemic Age | 2001 |
Insulin and glucose excursion following premeal insulin lispro or repaglinide in cystic fibrosis-related diabetes.
Topics: Adult; Blood Glucose; Carbamates; Cystic Fibrosis; Diabetes Mellitus; Female; Food; Humans; Hypoglyc | 2001 |
Streptozotocin for insulinoma.
Topics: Adenoma, Islet Cell; Adult; Antibiotics, Antineoplastic; Carbamates; Female; Glucosamine; Humans; Hy | 1971 |
Carbohydrate metabolism in normal and hyperglycemic animals treated with 1-methyl-4-(3-methyl-5-isoxazolyl)pyridinium chloride and phenformin.
Topics: Animals; Blood Glucose; Carbamates; Carbohydrate Metabolism; Diabetes Mellitus; Diabetes Mellitus, E | 1971 |